Data as of Apr 17
| +0.39 / +5.51%|
The 5 analysts offering 12-month price forecasts for Cardiome Pharma Corp have a median target of 10.85, with a high estimate of 14.00 and a low estimate of 3.50. The median estimate represents a +45.27% increase from the last price of 7.47.
The current consensus among 4 polled investment analysts is to Buy stock in Cardiome Pharma Corp. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.